Cognitive impairment in men with testicular cancer prior to adjuvant therapy

Cancer

Volumn 117, Issue 1, 2011, Pages 190-196

  Wefel, Jeffrey S ^a   Vidrine, Damon J ^a   Veramonti, Tracy L ^b   Meyers, Christina A ^a   Marani, Salma K ^a   Hoekstra, Harald J ^c   Hoekstra Weebers, Josette E H M ^c,d   Shahani, Lokesh ^e   Gritz, Ellen R ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Mentis Neuro Rehabilitation   (United States)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d Integraal Kankercentrum Noord Nederland   (Netherlands)

^e SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cognition disorders; orchiectomy; quality of life; testicular neoplasms

Indexed keywords

ADULT; ANXIETY; ARTICLE; ATTENTION; CANCER ADJUVANT THERAPY; COGNITIVE DEFECT; CONTROLLED STUDY; DEPRESSION; HUMAN; LANGUAGE ABILITY; LEARNING DISORDER; MAJOR CLINICAL STUDY; MALE; MENTAL FUNCTION; MOTOR DYSFUNCTION; NEUROPSYCHOLOGICAL TEST; NON SEMINOMATOUS GERMINOMA; ORCHIECTOMY; PRIORITY JOURNAL; QUALITY OF LIFE; SELF REPORT; TESTIS CANCER;

ANTINEOPLASTIC AGENTS; ATTENTION; CHEMOTHERAPY, ADJUVANT; COGNITION DISORDERS; COMBINED MODALITY THERAPY; EXECUTIVE FUNCTION; HUMANS; MALE; MEMORY; MOTOR SKILLS; NEOPLASMS, GERM CELL AND EMBRYONAL; NEUROPSYCHOLOGICAL TESTS; ORCHIECTOMY; SPEECH-LANGUAGE PATHOLOGY; TESTICULAR NEOPLASMS;

EID: 78650717423     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25298     Document Type: Article

References (38)

1. Wefel JS, Lenzi R, Theriault R, Buzdar AU, Cruickshank S, Meyers CA,. 'Chemobrain' in breast carcinoma?: a prologue. Cancer. 2004; 101: 466-475.
2. Cimprich B, So H, Ronis DL, Trask C,. Pre-treatment factors related to cognitive functioning in women newly diagnosed with breast cancer. Psychooncology. 2005; 14: 70-78.
3. Hermelink K, Untch M, Lux MP, et al. Cognitive function during neoadjuvant chemotherapy for breast cancer: results of a prospective, multicenter, longitudinal study. Cancer. 2007; 109: 1905-1913. (Pubitemid 46668557)
4. Ahles TA, Saykin AJ, McDonald BC, et al. Cognitive function in breast cancer patients prior to adjuvant treatment. Breast Cancer Res Treat. 2008; 110: 143-152.
5. WITHDRAWN., Mohile SG, Lacy M, Rodin M, Bylow K, Dale W, Meager MR, et al. Cognitive effects of androgen deprivation therapy in an older cohort of men with prostate cancer. Crit Rev Oncol Hematol. 2009. This article has been withdrawn from Critical Reviews in Oncology/Hematology. With the permission of the authors, it has been published in volume 1, issue 1 of the Journal of Geriatric Oncology ().
6. Meyers CA, Byrne KS, Komaki R,. Cognitive deficits in patients with small cell lung cancer before and after chemotherapy. Lung Cancer. 1995; 12: 231-235.
7. Wefel JS, Lenzi R, Theriault RL, Davis RN, Meyers CA,. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer. 2004; 100: 2292-2299.
8. Groll RJ, Warde P, Jewett MA,. A comprehensive systematic review of testicular germ cell tumor surveillance. Crit Rev Oncol Hematol. 2007; 64: 182-197.
9. Hoenig DM, Santos-Cortes JA, Rechtschaffen TH,. Nonseminomatous Testicular Tumors, 2009. Available at:.
10. Cotran RS, Kumar V, Robbins SL,. Robbins Pathologic Basis of Disease. Philadelphia: W.B. Saunders; 1994.
11. Radloff RS,. The CES-D Scale: a self-report depression scale for research in the general population. Appl Psychol Meas. 1977; 1: 385-401.
12. Speilberger CD, Gorsuch RL, Lushene R, Vagg PR, Jacobs GA,. The State-Trait Anxiety Inventory. Palo Alto, CA: Consulting Psychologists Press; 1983.
13. Zich JM, Attkisson CC, Greenfield TK,. Screening for depression in primary care clinics: the CES-D and the BDI. Int J Psychiatry Med. 1990; 20: 259-277.
14. Geisser ME, Roth RS, Robinson ME,. Assessing depression among persons with chronic pain using the Center for Epidemiological Studies-Depression Scale and the Beck Depression Inventory: a comparative analysis. Clin J Pain. 1997; 13: 163-170.
15. Green FL, Fritz AG, Balch CM, et al. AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer; 2002.
16. International Germ Cell Cancer Collaborative Group. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol. 1997; 15: 594-603.
17. Ingraham LJ, Aiken CB,. An empirical approach to determining criteria for abnormality in test batteries with multiple measures. Neuropsychology. 1996; 10: 120-124.
18. Bender CM, Sereika SM, Berga SL, et al. Cognitive impairment associated with adjuvant therapy in breast cancer. Psychooncology. 2006; 15: 422-430.
19. Hurria A, Rosen C, Hudis C, et al. Cognitive function of older patients receiving adjuvant chemotherapy for breast cancer: a pilot prospective longitudinal study. J Am Geriatr Soc. 2006; 54: 925-931. (Pubitemid 43847029)
20. Jenkins V, Shilling V, Deutsch G, et al. A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Br J Cancer. 2006; 94: 828-834.
21. Schagen SB, Boogerd W, Muller MJ, et al. Cognitive complaints and cognitive impairment following BEP chemotherapy in patients with testicular cancer. Acta Oncol. 2008; 47: 63-70.
22. Schweyer S, Soruri A, Peters J, Wagner A, Radzun HJ, Fayyazi A,. Malignant germ cell tumours of the testis express interferon-gamma, but are resistant to endogenous interferon-gamma. Br J Cancer. 2003; 89: 915-921.
23. Meyers CA, Albitar M, Estey E,. Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer. 2005; 104: 788-793.
24. Miller AH, Ancoli-Israel S, Bower JE, Capuron L, Irwin MR,. Neuroendocrine-immune mechanisms of behavioral comorbidities in patients with cancer. J Clin Oncol. 2008; 26: 971-982.
25. Lee BN, Dantzer R, Langley KE, et al. A cytokine-based neuroimmunologic mechanism of cancer-related symptoms. Neuroimmunomodulation. 2004; 11: 279-292.
26. McAfoose J, Baune BT,. Evidence for a cytokine model of cognitive function. Neurosci Biobehav Rev. 2009; 33: 355-366.
27. Ahern GL, O'Connor M, Dalmau J, et al. Paraneoplastic temporal lobe epilepsy with testicular neoplasm and atypical amnesia. Neurology. 1994; 44: 1270-1274.
28. Voltz R, Gultekin SH, Rosenfeld MR, et al. A serologic marker of paraneoplastic limbic and brain-stem encephalitis in patients with testicular cancer. N Engl J Med. 1999; 340: 1788-1795.
29. Gultekin SH, Rosenfeld MR, Voltz R, Eichen J, Posner JB, Dalmau J,. Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain. 2000; 123 (pt 7): 1481-1494.
30. Hoffmann LA, Jarius S, Pellkofer HL, et al. Anti-Ma and anti-Ta associated paraneoplastic neurological syndromes: 22 newly diagnosed patients and review of previous cases. J Neurol Neurosurg Psychiatry. 2008; 79: 767-773.
31. Gritz ER, Wellisch DK, Landsverk JA,. Psychosocial sequelae in long-term survivors of testicular cancer. J Psychosoc Oncol. 1988; 6: 41-63.
32. Pedersen AD, Rossen P, Mehlsen MY, Pedersen CG, Zachariae R, von der Maase H,. Long-term cognitive function following chemotherapy in patients with testicular cancer. J Int Neuropsychol Soc. 2009; 15: 296-301.
33. Vardy J, Wefel JS, Ahles T, Tannock IF, Schagen SB,. Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice cognitive workshop. Ann Oncol. 2008; 19: 623-629.
34. Wechsler D,. Wechsler Adult Intelligence Scale-Revised. San Antonio, TX: The Psychological Corporation; 1981.
35. Reitan RM,. Trail Making Test Manual for Administration and Scoring. Tucson, AZ: Reitan Neuropsychology Laboratory; 1992.
36. Benton AL, Hamsher K,. Multilingual Aphasia Examination. Iowa City, IA: AJA Associates; 1983.
37. Brandt J,. The Hopkins Verbal Learning Test: development of a new memory test with 6 equivalent forms. Clin Neuropsychol. 1991; 5: 125-142.
38. Trites R,. Neuropsychological Test Manual. Ottawa, ON: Royal Ottawa Hospital; 1977.